Fludeoxyglucose f-18

Fludeoxyglucose F-18 (also known as 18F-FDG) is a radiopharmaceutical used in the medical imaging modality positron emission tomography (PET). It is an isotope of glucose that allows doctors to observe metabolic processes in the body.

History[edit | edit source]

Fludeoxyglucose F-18 was first synthesized in the 1970s as a radiotracer for use in nuclear medicine. It was approved by the Food and Drug Administration (FDA) in 1994 for use in oncology, cardiology, and neurology.

Production[edit | edit source]

Fludeoxyglucose F-18 is produced by bombarding a target of oxygen-18 enriched water with high-energy protons in a cyclotron. The resulting F-18 isotope is then incorporated into a glucose molecule to form 18F-FDG.

Use in Medical Imaging[edit | edit source]

In medical imaging, 18F-FDG is used to detect abnormalities in glucose metabolism, a common indicator of disease. It is most commonly used in oncology to detect and monitor the progress of cancer, but it is also used in cardiology to assess heart tissue viability and in neurology to diagnose and monitor neurodegenerative diseases such as Alzheimer's disease.

Safety and Side Effects[edit | edit source]

As with any medical procedure, there are potential risks and side effects associated with the use of 18F-FDG. These can include allergic reactions, radiation exposure, and false-positive results. However, the benefits of 18F-FDG PET imaging often outweigh these risks.